Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein–Barr virus-positive diffuse large B-cell lymphoma - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Case Study: Challenges in Diagnosis and Biomarker-Driven Treatment of CD20-Negative Epstein–Barr Virus-Positive Diffuse Large B-Cell Lymphoma

  • By

  • Jingjing Wen

  • Chenxing Zhao

  • Shaozhen Chen

  • Xiurong Chen

  • Qinghu Lv

  • Wei Liu

  • Jiesong Wang

  • Daoguang Chen

  • August 24, 2026

Share

  • 1

    CD20-negative EBV+ DLBCL, NOS is a rare subtype of diffuse large B-cell lymphoma complicating diagnosis and treatment options.

  • 2

    The absence of CD20 restricts the use of anti-CD20 antibodies and expands the differential diagnosis for lymphomas.

  • 3

    Integrated immunophenotypic and molecular analyses were crucial for accurate diagnosis of the patient's lymphoma subtype.

  • 4

    The patient received biomarker-guided treatment, including CD30-targeted therapy and PD-1 blockade, resulting in a complete metabolic response.

  • 5

    This case emphasizes the need for prospective evaluation of CD20-independent treatment strategies in high-risk lymphoma patients.

Original Source(s)

Case Report: Diagnostic pitfall and biomarker-guided therapy in CD20-negative Epstein–Barr virus-positive diffuse large B-cell lymphoma

  • by Jingjing Wen, Chenxing Zhao, Shaozhen Chen, Xiurong Chen, Qinghu Lv, Wei Liu, Jiesong Wang, Daoguang Chen

  • August 24, 2026

Related Content

Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth

Correction to: Prognostic factors and nomogram development for adult diffuse large B-cell lymphoma: a single-center retrospective cohort study

Correction: Deep learning accurately and reliably segments pelvic vascular structure in CT scans of gynecologic cancer patients